Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model.

24 Jun, 2022 | 11:07h | UTC

Dysplastic Recurrence After Successful Treatment for Early Barrett’s Neoplasia: Development and Validation of a Prediction Model – Gastroenterology

 


Single-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.

24 Jun, 2022 | 10:49h | UTC

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

 


Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma.

24 Jun, 2022 | 10:46h | UTC

Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

News Release: Non-invasive liquid biopsy tracks cancer treatment success in real time – University of Wisconsin–Madison

Commentary: Longitudinal Liquid Biopsy for Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – The ASCO Post

 

Commentary on Twitter

 


Consensus report on anatomy, pathophysiology and clinical significance of the gastro-esophageal junction.

23 Jun, 2022 | 10:26h | UTC

Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction – Gut

 


International consensus statements on pre-invasive vulvar lesions.

23 Jun, 2022 | 10:21h | UTC

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions – International Journal of Gynecological Cancer

News Release: New Guidelines Address Treatment of Pre-Invasive Lesions of the Vulva – Wolters Kluwer Health: Lippincott

 


M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.

23 Jun, 2022 | 10:10h | UTC

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis – Cochrane Library

Summary: Which combinations of medicines are best for the prevention and treatment of anaemia in people with cancer? – Cochrane Library

 


Phase II RCT: FLOT vs. FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma.

23 Jun, 2022 | 09:58h | UTC

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.

23 Jun, 2022 | 09:57h | UTC

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment – Journal of Clinical Oncology

 


Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.

23 Jun, 2022 | 09:54h | UTC

Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials – Cancer Treatment and Research Communications

 


ASCO Guideline: Management of metastatic clear cell renal cell carcinoma.

22 Jun, 2022 | 11:30h | UTC

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline – Journal of Clinical Oncology

 


Cohort Study: Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment.

22 Jun, 2022 | 10:51h | UTC

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment – The Oncologist

Commentaries:

Polypharmacy can lead to harmful drug interactions, especially among cancer patients – News Medical

Analysis Underscores Risks of Polypharmacy in Elderly Patients With Cancer – AJMC

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 


Phase II RCT: Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer.

22 Jun, 2022 | 10:49h | UTC

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Switch to Maintenance Endocrine Therapy Plus Bevacizumab After First-Line Paclitaxel/Bevacizumab Induction in Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer – The ASCO Post

 


Long-term follow-up of a RCT: Nivolumab plus cabozantinib vs. sunitinib in first-line treatment for advanced renal cell carcinoma.

22 Jun, 2022 | 10:48h | UTC

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC – medwire News

Original Study: Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine

 

Commentary from the author on Twitter (thread – click for more)

 


RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.

21 Jun, 2022 | 11:11h | UTC

News Release: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health

Original Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Consensus definition and management recommendations: intermediate-risk non–muscle-invasive bladder cancer.

21 Jun, 2022 | 10:52h | UTC

Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (if the link is paywalled, try this one)

 

Commentary from the author on Twitter

 


RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.

21 Jun, 2022 | 10:48h | UTC

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


Onconephrology: Update in anticancer drug-related nephrotoxicity.

21 Jun, 2022 | 10:47h | UTC

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron

Related:

Acute Kidney Injury in Critically Ill Patients with Cancer – Clinical Journal of the American Society of Nephrology

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents – Kidney Research and Clinical Practice

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer – Kidney International

 

Commentary from the author on Twitter

 


RCT: Active surveillance plus Enzalutamide monotherapy vs. active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer.

21 Jun, 2022 | 10:33h | UTC

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer – JAMA Oncology

Invited Commentary: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (free for a limited period)

Video criticizing the article: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad

 

Commentaries on Twitter

 


Clinical and immunologic analyses of a phase II trial: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer.

21 Jun, 2022 | 10:26h | UTC

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial – Nature Medicine

News Release: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania

 

Commentary on Twitter

 


NCCN Updated Guideline: Breast cancer.

20 Jun, 2022 | 01:24h | UTC

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

 


Single-arm phase 2b study: MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer.

20 Jun, 2022 | 00:56h | UTC

MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link to abstract – $ for full-text)

News Release: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects – Memorial Sloan Kettering Cancer Center

 

Commentary on Twitter

 


Radiomic assessment of esophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT.

20 Jun, 2022 | 00:53h | UTC

Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT – Insights into Imaging

 


Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.

20 Jun, 2022 | 00:51h | UTC

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi – Journal of Clinical Oncology

 


Cohort Study: Association of screening with digital breast tomosynthesis vs. digital mammography with risk of interval invasive and advanced breast cancer.

17 Jun, 2022 | 11:09h | UTC

Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (free for a limited period)

Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (free for a limited period)

News Release: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco

 


Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients.

15 Jun, 2022 | 10:49h | UTC

Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients – Science Bulletin

News Release: Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer – Science China Press

 


Stay Updated in Your Specialty

No spam, just news.